Selective estrogen-receptor (ER) modulators, such as tamoxifen, have been the gold standard of care for women with HR+ breast cancer for the last 30 years (Jordan, 2004; Geisler et al, 2008). The gene discussed is ESR1; the disease is breast cancer.